MYGN
Myriad Genetics Inc
NASDAQ · Biotechnology
$5.12
+0.02 (+0.39%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 861.76M | 808.10M | 75.18M | 74.53M | 73.26M |
| Net Income | -130,974,596 | -110,537,449 | -15,172,295 | -15,758,896 | -11,828,489 |
| EPS | — | — | — | — | — |
| Profit Margin | -15.2% | -14.4% | -20.2% | -21.1% | -16.2% |
| Rev Growth | +6.6% | +6.6% | -4.8% | +5.3% | -4.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 12.76M | 12.76M | 121.64M | 122.72M | 106.53M |
| Total Equity | 225.87M | 225.87M | 219.95M | 215.66M | 214.57M |
| D/E Ratio | 0.06 | 0.06 | 0.55 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -62,965,867 | -56,092,998 | -16,149,167 | -16,042,014 | -17,865,875 |
| Free Cash Flow | — | — | -9,917,338 | -13,316,178 | -13,196,312 |